Among the 50 entrants in the competition, Glycotope was selected as the winner for the innovative nature and commercial impact of its GlycoExpress^TM technology of human cell lines to develop and manufacture biopharmaceuticals with an improved glycosylation
leading to potentially significant therapeutic and economic benefits.

Dr. Steffen Goletz, CEO, CSO & Founder of Glycotope is "proud, that in winning the award, Glycotope is joining technological leaders such as Thermo Fisher Scientific Inc., BASF, Novozymes A/S, DSM or Dow Pharmaceutical Sciences Inc."